Silence Therapeutics' divesiran meets Phase 2 endpoints in blood cancer trial

August 10, 2026 7:30 AM

Silence Therapeutics plc (Nasdaq: SLN) announced positive topline results from the Phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found